1. A pharmaceutical preparation for the prevention or treatment of a disorder accompanied by ocular angiogenesis and / or increased vascular permeability of the eye, consisting of a combination of an anti-VEGF agent and a hydantoin derivative represented by the general formula (I): in this formula, X represents a halogen atom or a hydrogen atom , a R and R simultaneously or separately represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or a pharmacologically acceptable salt thereof. 2. The pharmaceutical preparation according to claim 1, wherein the hydantoin derivative represented by the general formula (I) is (2S, 4S) -6-fluoro-2 ', 5'-dioxospiro [chroman-4,4'-imidazolidine] -2 β-carboxamide. 3. The pharmaceutical preparation according to claim 1, wherein the anti-VEGF agent is at least one species selected from the group consisting of an anti-VEGF antibody, a VEGF ligand inhibitor, a VEGF receptor antagonist, and an oligonucleotide drug related to VEGF. 4. The pharmaceutical preparation according to claim 1, wherein the disorder accompanied by ocular angiogenesis and / or increased vascular permeability of the eye is selected from the group consisting of age-related macular degeneration, retinal vein occlusion, central retinal vein occlusion, diabetic maculopathy, diabetic retinopathy and neovascular glaucoma .5. A pharmaceutical preparation for the prevention or treatment of a disorder accompanied by ocular angiogenesis and / or increased vascular permeability of the eye vessels containing a hydantoin derivative represented by the general formula (I): in this formula X represents a halogen atom or a hydrogen atom, a R and R simultaneously or �1. Фармацевтический препарат для предупреждения или лечения нарушения, сопровождающегося глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза, состоящий из сочетания анти-VEGF средства и производного гидантоина, представленного общей формулой (I):в данной формуле Х представляет собой атом
